---
title: "Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296248178.md"
description: "The market for non-metastatic prostate cancer is projected to experience substantial expansion due to the rise in disease awareness, enhanced screening methods, and advancements in early-stage detection. The presence of a burgeoning therapy pipeline including Relugolix (ORGOVYX) by Myovant/Sumitomo is contributing to this growth. This sector shows promising potential for development, with a notable increase in patients benefiting from improved treatment options."
datetime: "2026-08-18T14:57:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296248178.md)
  - [en](https://longbridge.com/en/news/296248178.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296248178.md)
generator: "portal-rs"
---

# Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight

The market for non-metastatic prostate cancer is projected to experience substantial expansion due to the rise in disease awareness, enhanced screening methods, and advancements in early-stage detection. The presence of a burgeoning therapy pipeline including Relugolix (ORGOVYX) by Myovant/Sumitomo is contributing to this growth. This sector shows promising potential for development, with a notable increase in patients benefiting from improved treatment options.

### Related Stocks

- [4506.JP](https://longbridge.com/en/quote/4506.JP.md)

## Related News & Research

- [Sumitomo Pharma (TSE:4506) Reports Strong First Quarter Earnings, Is The Discount Too Deep?](https://longbridge.com/en/news/295441766.md)
- [Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast](https://longbridge.com/en/news/294406043.md)
- [10:31 ETLiver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight](https://longbridge.com/en/news/296802956.md)
- [Oncoinvent publishes corporate presentation on Radspherin alpha therapy for peritoneal metastases](https://longbridge.com/en/news/296475294.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**